{
    "clinical_study": {
        "@rank": "87296", 
        "brief_summary": {
            "textblock": "Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes\n      of intravitreal anti-VEGF therapy for eAMD."
        }, 
        "brief_title": "Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes", 
        "completion_date": {
            "#text": "February 2010", 
            "@type": "Actual"
        }, 
        "condition": [
            "Epiretinal Membrane", 
            "Age Related Macular Degeneration"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Epiretinal Membrane"
            ]
        }, 
        "detailed_description": {
            "textblock": "Gass in 1987 described three cases of epiretinal membrane (ERM) associated with wet macular\n      degeneration.  Since then we have seen that is not rare to find the coexistence of these\n      entities. An ERM may produce intrinsic disorganization of the outer retina leading to\n      persistent increased macular thickness and/or edema. This persistent edema may affect the\n      effectiveness in the treatment of exudative age-related macular degeneration (eAMD).\n      Therefore, this study was designed to evaluate the effect of significant ERM on the visual\n      and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Significant epiretinal membrane\n\n          -  Anti-VEGF treatment for age-related macular degeneration\n\n        Exclusion Criteria:\n\n          -  Uveitis\n\n          -  Macular disorders\n\n          -  Diabetic retinopathy\n\n          -  Vascular occlusions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "58 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "age-related macular degeneration"
            }
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01846351", 
            "org_study_id": "NAC270608"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "choroidal neovascularization", 
            "epiretinal membrane", 
            "anti-VEGF"
        ], 
        "lastchanged_date": "May 1, 2013", 
        "number_of_groups": "1", 
        "official_title": "Visual and Anatomic Outcomes of Intravitreal Anti-VEGF Therapy for Exudative Age-related Macular Degeneration With Concurrent Significant Epiretinal Membrane.", 
        "overall_official": [
            {
                "affiliation": "New England Retina Associates", 
                "last_name": "Nauman A Chaudhry, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "New England Retina Associates", 
                "last_name": "Peter E Liggett, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Evaluate the best visual acuity during the follow up.", 
                "measure": "Best corrected visual acuity", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Evaluation of the retinal thickness changes with anti-VEGF treatment", 
                "measure": "Central macular thickness", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Evaluation of changes in lesion size during follow-up.", 
                "measure": "Fluorescein angiogram", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01846351"
        }, 
        "responsible_party": {
            "investigator_affiliation": "New England Retina Associates", 
            "investigator_full_name": "Peter E. Liggett", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "New England Retina Associates", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "New England Retina Associates", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2006", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}